Skip to content

MIRA Pharmaceuticals, Inc.: 10-Q filed 2025-11-13

What MIRA Pharmaceuticals, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 25 published measures, 79 facts as tagged in accession 0001493152-25-022112.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-022112 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MIRA Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-307,633,280USD
At 2024-12-312,923,099USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3083,926USD
At 2024-12-31723,349USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-307,549,354USD
At 2025-06-30569,859USD
At 2025-03-311,294,165USD
At 2024-12-312,199,750USD
At 2024-09-303,573,737USD
At 2024-06-302,218,966USD
At 2024-03-313,156,785USD
At 2023-12-314,374,346USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-302,641,539USD
At 2024-12-312,832,931USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,137,673USD92
2025-01-01 to 2025-09-30-4,459,164USD273
2025-04-01 to 2025-06-30-1,537,712USD91
2025-01-01 to 2025-03-31-1,783,779USD90
2024-07-01 to 2024-09-30-2,043,867USD92
2024-01-01 to 2024-09-30-5,452,963USD274
2024-04-01 to 2024-06-30-1,691,325USD91
2024-01-01 to 2024-03-31-1,717,771USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-3,526,632USD273
2024-01-01 to 2024-09-30-3,755,576USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,335,240USD273
2024-01-01 to 2024-09-303,297,570USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-33,596,885USD
At 2024-12-31-29,137,721USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3019,274,947shares92
2025-01-01 to 2025-09-3017,984,641shares273
2024-07-01 to 2024-09-3015,071,915shares92
2024-01-01 to 2024-09-3015,071,915shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3019,274,947shares92
2025-01-01 to 2025-09-3017,984,641shares273
2024-07-01 to 2024-09-3015,071,915shares92
2024-01-01 to 2024-09-3015,071,915shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.18USD/shares92
2025-01-01 to 2025-09-30-1.45USD/shares273
2024-07-01 to 2024-09-30-0.14USD/shares92
2024-01-01 to 2024-09-30-0.36USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.18USD/shares92
2025-01-01 to 2025-09-30-1.45USD/shares273
2024-07-01 to 2024-09-30-0.14USD/shares92
2024-01-01 to 2024-09-30-0.36USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,755,218USD273
2024-01-01 to 2024-09-301,374,024USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-307,597,841USD
At 2024-12-312,887,660USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3083,926USD
At 2024-12-31723,349USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-3083,926USD
At 2024-12-31423,349USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,316,985USD92
2025-01-01 to 2025-09-304,668,285USD273
2024-07-01 to 2024-09-302,081,619USD92
2024-01-01 to 2024-09-305,580,527USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30412,639USD92
2025-01-01 to 2025-09-301,223,240USD273
2024-07-01 to 2024-09-301,067,396USD92
2024-01-01 to 2024-09-302,444,134USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3039,511,492shares
At 2024-12-3116,560,852shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3041,142,288USD
At 2024-12-3131,335,815USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-12-31300,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-22,694,494USD92
2025-01-01 to 2025-09-30-26,015,985USD273
2024-07-01 to 2024-09-30-2,043,867USD92
2024-01-01 to 2024-09-30-5,452,963USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30904,346USD92
2025-01-01 to 2025-09-303,445,045USD273
2024-07-01 to 2024-09-301,014,223USD92
2024-01-01 to 2024-09-303,136,393USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30179,312USD92
2025-01-01 to 2025-09-30209,121USD273
2024-07-01 to 2024-09-3037,752USD92
2024-01-01 to 2024-09-30127,564USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,171,497USD273
2024-01-01 to 2024-09-303,129,626USD274

Inspect the source

Entity
MIRA Pharmaceuticals, Inc. / CIK 0001904286
Captured
2026-09-21T17:34:21.997Z
SEC response SHA-256
6aa4bc18e2db927c9ebd1545787e0d49f72409a116e95d3e89ec579fe3d8d732

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001904286.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))